Clinical guide to managing low-dose naltrexone (LDN) overdose and accidental excess doses, including symptoms, timelines, opioid receptor blockade duration, and when to seek emergency care.
A clinical review of naltrexone's patent history, current compounding status, FDA-approved formulations, and the regulatory path for a dedicated low-dose naltrexone product.
A clinician-grade review of low-dose naltrexone (LDN) safety signals, FDA regulatory actions, compounding pharmacy oversight, and adverse-event data from published trials and FAERS reports.
Evidence-based guide to using low-dose naltrexone (LDN) in special populations including transplant recipients, people living with HIV, cancer patients, pregnant individuals, children, and those with hepatic or renal impairment.
Evidence-based guide to low-dose naltrexone dosing in young adults aged 18 to 29, covering titration schedules, fertility considerations, and clinical monitoring.
Does testosterone replacement therapy cause aggression or mood swings? A clinical breakdown of TRT's psychological effects, risk factors, and monitoring strategies backed by trial data.
A detailed breakdown of online TRT prices in 2026, including monthly costs by medication type, insurance and Medicare coverage, prior authorization steps, and how to compare telehealth clinic pricing.
Testosterone replacement therapy can worsen obstructive sleep apnea. Learn the clinical evidence, screening requirements, and management strategies for men on TRT.
Learn how hormone replacement therapy affects hair growth and shedding. Covers TRT, female HRT, DHT, finasteride, and evidence-based strategies to protect your hair during treatment.
A clinical case study exploring how one woman navigated PCOS diagnosis, treatment options, and long-term management with evidence-based care.
Learn how to interpret CBC, CMP, lipid panels, hormone levels, and metabolic markers on your lab report. Understand reference ranges, optimal zones, and red flags that matter most for men on TRT or hormone therapy.
Get testosterone shots via primary care, urology, men's clinics, telehealth, or self-injection at home. Compare cost, convenience, and oversight for each option.
Learn why desire can fall around menopause, what research shows on hormones and testosterone, and which drugs are approved for low desire.
Evidence-based metformin monitoring guide for adults aged 30 to 49. Covers baseline labs, follow-up intervals, renal function tracking, B12 screening, and red flags that signal a dose change.
Evidence-based guide to metformin safety in adults 65 and older, covering renal dosing, lactic acidosis risk, B12 monitoring, drug interactions, and deprescribing criteria.
A clinical deep-dive into metformin's manufacturing origins, global supply chain, FDA shortage events, NDMA recalls, and current availability for type 2 diabetes treatment.
Evidence-based metformin monitoring schedule covering HbA1c, renal function, B12, hepatic panels, and CBC. Includes timing, thresholds, and when to adjust or stop.
A clinician-grade review of metformin's off-label applications beyond type 2 diabetes, ranked by strength of evidence from randomized trials, meta-analyses, and guideline endorsements.
Metformin labs to monitor: eGFR at least yearly, vitamin B12 every 2 to 3 years, and the lactic acidosis boxed warning for adults 50 to 64.
A physician-level review of metformin pharmacokinetics covering oral bioavailability, transporter-mediated uptake via OCT1/OCT2, zero hepatic metabolism, and renal tubular secretion. Includes dosing implications for eGFR thresholds.
Evidence-based review of metformin safety during pregnancy and breastfeeding, including MiG trial data, placental transfer, breast milk levels, and current ACOG/ADA guideline positions.
Learn which foods and supplements affect thyroid function, distort thyroid tests, or follow another medicine’s timing rules while taking methimazole.
Evidence-based guide to methimazole (Tapazole) storage conditions, chemical stability data, shelf life, and practical handling for patients and pharmacies.
Evidence-based guide to switching between methimazole and propylthiouracil, radioactive iodine, or thyroidectomy. Covers dose conversion ratios, pregnancy protocols, and monitoring timelines.
Evidence-based protocol for tapering and discontinuing MK-677 (ibutamoren), including timeline expectations, rebound effects, and monitoring recommendations.
A clinical review of MK-677 (ibutamoren) pipeline developments, emerging formulations, and the regulatory path forward for this oral GH secretagogue.
Evidence-based guide to MK-677 (ibutamoren) dosing in adults 65 and older, covering pharmacokinetics, GH/IGF-1 response, safety concerns, and monitoring protocols for geriatric patients.
MK-677 is not FDA-approved; in adults 65+ it can worsen heart failure via fluid retention, raise fall risk, and interact with common medications.
Evidence-based guide to MK-677 (ibutamoren) dosing in adults aged 50, 64, covering GH/IGF-1 physiology, trial data, safety monitoring, and age-specific considerations.
Evidence-based monitoring guide for MK-677 (ibutamoren) in adults aged 50-64. Covers IGF-1 tracking, glucose surveillance, cardiovascular screening, and age-specific safety protocols.
MK-677 (ibutamoren) is not approved by the FDA, EMA, Health Canada, or the MHRA. Learn the current regulatory classification, legal risks, and clinical trial evidence for this investigational GH secretagogue.
Evidence-based safety guide for modafinil (Provigil) in adults aged 30-49, covering cardiovascular risk, drug interactions, psychiatric effects, and monitoring recommendations.
A clinical comparison of Provigil (modafinil) pricing against armodafinil, pitolisant, solriamfetol, and traditional stimulants, with trial data, insurance coverage details, and practical switching guidance.
Evidence-based guide to modafinil food and supplement interactions, including caffeine, grapefruit, St. John's wort, and timing with meals. prepared by the HealthRX.com Editorial Team.
A complete timeline of modafinil (Provigil) from its 1974 synthesis in France through FDA approval, patent battles, and current clinical use for narcolepsy and shift-work disorder.
A detailed history of modafinil (Provigil) manufacturing, FDA supply chain events, generic entry, and shortage timelines with clinical context and primary source citations.
How to think about modafinil dosing in patients with chronic kidney disease, including FDA label guidance, what is known about metabolite handling, dialysis considerations, and a monitoring framework. Pending qualified clinical review.
A comprehensive review of modafinil (Provigil) safety signals, FDA regulatory actions, serious dermatologic reactions, psychiatric adverse events, and the rejected pediatric indication.
Evidence-based monitoring guide for MOTS-c mitochondrial peptide in adults aged 30-49. Covers baseline labs, metabolic markers, glucose tracking, safety signals, and recommended check-in schedules.
MOTS-c has no approved product or published cost. Learn what FDA found, why no human data exists, and how HHS's draft policy names six peptides.
Evidence-based analysis of MOTS-c mitochondrial peptide drug-drug interactions, including metformin, insulin sensitizers, folate antagonists, and AMPK-modulating agents.
Evidence-based guide to MOTS-c mitochondrial peptide interactions with foods, supplements, and common co-administered compounds. Reviewed by board-certified physicians.
A clinical review of MOTS-c mitochondrial peptide pipeline developments, emerging formulations, delivery innovations, and the research trajectory toward human trials.
MOTS-c evidence in older adults, separating mouse experiments, endogenous human measurements, trial age limits, and unstudied administered-human safety.
A clinical review of MOTS-c mitochondrial peptide manufacturing processes, supply chain challenges, and shortage history, with PubMed-cited evidence on synthesis methods and quality control.
A physician-level breakdown of how MOTS-c, a 16-amino-acid mitochondrial-derived peptide, activates AMPK through folate cycle inhibition, translocates to the nucleus under metabolic stress, and regulates glucose homeostasis.
Evidence-based guidance on handling a missed MOTS-c mitochondrial peptide dose, including timing windows, resumption strategies, and pharmacokinetic considerations for this investigational metabolic peptide.
What to do after suspected MOTS-c excess: emergency triage, Poison Control, product identification, and the lack of human toxicity thresholds.
How mitochondrial DNA variants, especially m.1382A>C, alter MOTS-c peptide function, circulating levels, and metabolic response. Evidence-based pharmacogenomic analysis for clinicians.
A renal evidence audit for MOTS-c, separating endogenous CKD and hemodialysis biomarkers from missing administered-human pharmacokinetics and dosing data.
A source-led MOTS-c storage guide separating product-specific stability and beyond-use dates from unsupported generic peptide shelf-life rules.
Evidence-based monitoring protocols for MOTS-c mitochondrial peptide use in young adults aged 18, 29, including baseline labs, follow-up intervals, fertility considerations, and safety parameters.
MOTS-c and autoimmune evidence, distinguishing NOD-mouse treatment, ex vivo T-cell findings, endogenous biomarkers, and unstudied human use.
Evidence-based monitoring protocol for tirzepatide (Mounjaro) in adults aged 30 to 49, covering labs, GI tracking, thyroid surveillance, and dose-titration decision points.
Evidence-based safety profile of Mounjaro (tirzepatide) for adults aged 30 to 49, including adverse event rates from SURPASS trials, GI tolerability, and monitoring recommendations.
Evidence-based guidance on how to safely stop Mounjaro (tirzepatide), including taper schedules, weight regain data from SURMOUNT-4, blood sugar monitoring, and what to expect after discontinuation.
Evidence-based guide to Mounjaro (tirzepatide) dosing in adults 65 and older, covering titration schedules, renal adjustments, fall risk, GI tolerability, and deprescribing strategies.
Evidence-based monitoring framework for tirzepatide (Mounjaro) in adults 65 and older, covering renal function, nutritional status, fall risk, and deprescribing considerations.
Evidence-based guide to managing a Mounjaro (tirzepatide) overdose or accidental double dose, including symptoms, timelines, when to seek emergency care, and clinical protocols.
A detailed analysis of Eli Lilly's tirzepatide (Mounjaro) patent portfolio, expected generic entry dates, Paragraph IV challenges, and what patients should expect for biosimilar and generic availability.